Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- AZ Divests Rights to Develop, Sell GI Treatment Entocort Worldwide Excluding US to Tillotts
July 10, 2015
- Anti-PCSK9 Antibody Demonstrates Favorable Results in PIII Study for Japanese Patients: Sanofi, Regeneron
July 10, 2015
- Doctors Desire New Drugs for Dementia in Japan: Survey
July 9, 2015
- AbbVie to Initiate Clinical Study of Antibody-Drug Conjugate ABT-414 for Malignant Glioma in Japan
July 9, 2015
- Ethical Drug Sales Unchanged in May: Crecon Report
July 8, 2015
- Sawai Gearing Up to Revise 3-Year Biz Plan after New Generic Target
July 8, 2015
- Towa to Issue Convertible Bonds with Face Value of 15 Billion Yen
July 8, 2015
- ASCO Immunotherapy Roundup - 1: Opdivo Data Boost Confidence in BMS’s Combination Strategy
July 7, 2015
- Series: ASCO Immunotherapy Roundup
July 7, 2015
- Japan, US, Europe Anti-Infective Agent Markets Grow 48.4% in FY2014 Driven by Anti-HCV Treatments: Survey
July 7, 2015
- Foreign Drug Makers’ Sales Dip on Generic Inroads in 2014
July 6, 2015
- Multiple Myeloma Treatment Farydak Approved: Novartis
July 6, 2015
- Once-Weekly GLP-1 Receptor Agonist Trulicity Approved: Eli Lilly Japan
July 6, 2015
- Idiopathic Pulmonary Fibrosis Treatment OFEV Approved: NBI
July 6, 2015
- Immune Checkpoint Inhibitor Yervoy Approved for Malignant Melanoma: Bristol-Myers
July 6, 2015
- Lupus Erythematosus Treatment Plaquenil Approved: Sanofi
July 6, 2015
- Hepatitis C Treatment Harvoni Approved: Gilead Sciences
July 6, 2015
- MTPC Preparing to Submit Radicut for an Indication of ALS in the US
July 3, 2015
- Santen Files IND Application for Anti-Endoglin Antibody for Wet AMD in US
July 3, 2015
- President Tada to Double as Drug Development Head: Sumitomo Dainippon
July 3, 2015
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…